← Back to Search

PET Imaging for Pulmonary Arterial Hypertension

Phase < 1
Recruiting
Led By Stephen Chan
Research Sponsored by Stephen Y. Chan
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Controls: Age between 18-75 years old
Cases: Age between 18-75 years old
Must not have
Controls: History of radiation exposure at workplace
Cases: Inability to lie down for long period of time
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 90 minutes
Awards & highlights
No Placebo-Only Group

Summary

This trial uses a special PET scan with a tracer called 18F-FGln to study how a substance called glutamine is taken up in the lungs and heart of patients with different types of pulmonary arterial hypertension (PAH). The goal is to see if this method can help detect early stages of PAH and understand its progression. The study includes patients with various forms of PAH and healthy individuals for comparison.

Who is the study for?
This trial is for adults aged 18-75 with confirmed PAH or at low risk of heart/lung diseases. It's not for pregnant/breastfeeding women, smokers, those with certain job exposures, CT contrast allergies, claustrophobia, excessive alcohol consumption, or conditions making the study unsafe.
What is being tested?
[F-18]FGln PET imaging is being tested to see if it can non-invasively detect early stages of PAH by measuring glutamine metabolism in the lungs and heart. This could help diagnose PAH more quickly than current methods.
What are the potential side effects?
As [F-18]FGln is used for imaging purposes and involves lying down in a scanner without medication administration like typical drugs, side effects are minimal but may include discomfort from staying still and potential reactions to the tracer substance.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 75 years old.
Select...
I am between 18 and 75 years old.
Select...
I have been diagnosed with a specific type of pulmonary hypertension or scleroderma without PAH, confirmed by heart catheterization.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have been exposed to radiation at work.
Select...
I cannot lie down for long periods.
Select...
I cannot lie down for long periods.
Select...
I am under 18 years old.
Select...
I am under 18 years old.
Select...
I have been exposed to radiation at work.
Select...
My family has a history of Pulmonary Hypertension or Scleroderma.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~90 minutes
This trial's timeline: 3 weeks for screening, Varies for treatment, and 90 minutes for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
SUV or image-based threshold of 18F-FGNnon-diseased controls

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: 18F-FGLN PET ImagingExperimental Treatment2 Interventions
10.0 mCi of 18F-FGln will be injected intravenously as a slow bolus (20 sec)

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Pulmonary Arterial Hypertension (PAH) include phosphodiesterase-5 inhibitors (PDE5Is) like sildenafil and tadalafil, which work by relaxing pulmonary blood vessels to reduce resistance and improve blood flow. Endothelin receptor antagonists (ERAs) such as bosentan block endothelin, a substance that constricts blood vessels, thereby lowering blood pressure in the lungs. Prostacyclin analogs like epoprostenol dilate blood vessels and inhibit platelet aggregation. These treatments are crucial for managing PAH as they help alleviate symptoms, improve exercise capacity, and slow disease progression. Non-invasive imaging biomarkers like [F-18]FGln are being explored to monitor glutamine metabolism in PAH, offering potential for early detection and assessment of treatment response.
NMR-Based Metabolomic Analysis of Plasma in Patients with Adult Congenital Heart Disease and Associated Pulmonary Arterial Hypertension: A Pilot Study.Clinical trials in group 3 pulmonary hypertension.Efficacy and tolerability of pharmacological interventions for pulmonary arterial hypertension: A network meta-analysis.

Find a Location

Who is running the clinical trial?

BayerIndustry Sponsor
2,276 Previous Clinical Trials
25,540,644 Total Patients Enrolled
28 Trials studying Pulmonary Arterial Hypertension
6,670 Patients Enrolled for Pulmonary Arterial Hypertension
Stephen Y. ChanLead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)NIH
3,942 Previous Clinical Trials
47,793,167 Total Patients Enrolled
27 Trials studying Pulmonary Arterial Hypertension
3,160 Patients Enrolled for Pulmonary Arterial Hypertension
Stephen ChanPrincipal InvestigatorUniversity of Pittsburgh

Media Library

18F-FGLN PET Imaging Clinical Trial Eligibility Overview. Trial Name: NCT05452889 — Phase < 1
Pulmonary Arterial Hypertension Research Study Groups: 18F-FGLN PET Imaging
Pulmonary Arterial Hypertension Clinical Trial 2023: 18F-FGLN PET Imaging Highlights & Side Effects. Trial Name: NCT05452889 — Phase < 1
18F-FGLN PET Imaging 2023 Treatment Timeline for Medical Study. Trial Name: NCT05452889 — Phase < 1
~21 spots leftby Dec 2025